Type 2 Diabetes Accelerates Liver Fibrosis in Chronic Hepatitis B with Fatty Liver: Hepatology | May 2026

Introduction:

Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with concurrent hepatic steatosis.

Why was this study needed?

• The coexistence of CHB, fatty liver, and T2DM is becoming increasingly common.
• The impact of diabetes on liver fibrosis in CHB remains poorly understood.
• Viral and metabolic factors may contribute differently to liver injury.
• Better risk stratification is needed for patients with dual liver disease.
• Understanding these interactions may improve long-term management.

Results:

• Type 2 diabetes independently increased the risk of significant liver fibrosis in treatment-naïve CHB patients with hepatic steatosis.
• HBeAg positivity was primarily associated with hepatic inflammation, whereas higher BMI predicted more severe hepatic steatosis, highlighting distinct roles of viral and metabolic factors.
• These findings demonstrate that diabetes contributes to fibrosis progression independently of other metabolic syndrome components.

Clinical Impact:

This international study reinforces the need for a dual therapeutic approach in CHB patients with fatty liver. While antiviral therapy remains essential for viral control, aggressive management of diabetes may be equally important to slow fibrosis progression and improve long-term liver outcomes.

Bottom Line:

Type 2 diabetes is an independent driver of liver fibrosis in chronic hepatitis B patients with hepatic steatosis. Optimal management should address both viral replication and metabolic risk factors, particularly diabetes, to reduce the risk of progressive liver disease.